Goldman Sachs Upgrades ResMed (RMD) to Conviction Buy

April 26, 2013 9:48 AM

Goldman Sachs upgraded ResMed (NYSE: RMD) from Buy to Conviction Buy. Analyst Ian Abbott sees 14% potential return.

"We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found